If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Carl Ziegler

by Susan J. Ainsworth
December 10, 2012 | A version of this story appeared in Volume 90, Issue 50

Photo of Carl Ziegler.

Carl Ziegler, 60, a retired Pfizer chemist, died of cancer on Aug. 14.

Born in Columbia, Pa., Ziegler received a B.S. in chemistry in 1974 from Millersville University and an M.S. in organic chemistry in 1977 at the University of Delaware, working with Richard F. Heck on the development of the Heck reaction.

Ziegler earned a Ph.D. in organic chemistry in 1981 from Duke University under Ned A. Porter before conducting postdoctoral research with Sir Jack Baldwin at the University of Oxford and at Hoffmann-La Roche in Basel, Switzerland.

He then launched his career in 1984, serving as a group leader in Lederle Laboratories’ medical research division. In 1995, he joined Pfizer in Groton, Conn., where he remained until his retirement in 2012. He was a project leader in Pfizer’s veterinary medicine department, supervising the development of Draxxin, an antibacterial for the treatment of bovine respiratory disease. Later in his career, he was an associate research fellow, serving as a technical expert in patent law. Ziegler joined ACS in 1975.

In addition to coaching his sons’ recreational sports teams, Ziegler was also president of East Lyme Little League baseball for three years and an active member of the East Lyme Garden Club.

He is survived by his wife, Jillian, and sons, Robert and Philip.

Obituary notices of no more than 300 words may be sent to Susan J. Ainsworth at and should include an educational and professional history.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.